Author:
Yubero Alfonso,Estévez Purificación,Barquín Aránzazu,Sánchez Luisa,Santaballa Ana,Pajares Bella,Reche Piedad,Salvador Carmen,Manso Luis,Márquez Raúl,González-Martín Antonio
Subject
Obstetrics and Gynecology,Oncology
Reference15 articles.
1. The systemic treatment of recurrent ovarian cancer revisited;Baert;Ann Oncol.,2021
2. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial;Coleman;Lancet.,2017
3. PARPi after PARPi in epithelial ovarian cancer;Essel;Gynecol. Oncol. Rep.,2021
4. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial;Kristeleit;Lancet Oncol.,2022
5. Lynparza (olaparib) Prescribing Information. (Accessed 30 May 2023).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Multiple drugs;Reactions Weekly;2024-02-24